Management of Interstitial Cystitis/Bladder Pain Syndrome

Introduction to Treatment Guidelines

• The American Urological Association recommends beginning with behavioral modifications and dietary changes for all patients, then escalating systematically through oral medications, intravesical therapies, cystoscopy with hydrodistension, treatment of Hunner lesions if present, and reserving advanced interventions only for refractory cases that have failed all other treatments 1.

First-Line: Behavioral Modifications and Self-Care

• Patients should eliminate bladder irritants, including coffee, citrus products, and spicy foods from their diet, and implement an elimination diet to identify personal trigger foods 1, 2.
• Managing fluid intake strategically can help dilute urinary irritants and alter urine concentration 1, 2.
• Applying local heat or cold over the bladder or perineum can provide symptomatic pain relief 1, 2.
• Practicing stress management techniques, such as meditation and imagery, can help reduce symptom flares 1, 2.
• Performing pelvic floor muscle relaxation exercises, but not strengthening exercises, can help alleviate symptoms, and referral for manual physical therapy techniques may be considered 1, 2, 3.

Second-Line: Oral Medications

• Starting amitriptyline at 10 mg daily and titrating up to 100 mg per day as tolerated can provide symptom improvement with Grade B evidence 1, 2.
• Pentosan polysulfate sodium (Elmiron) 100 mg three times daily is the only FDA-approved oral medication for IC/BPS, but mandatory ophthalmologic monitoring is required due to risk of macular damage and ocular toxicity 1, 2.
• Alternative second-line oral options include cimetidine and hydroxyzine 2, 3.

Second-Line: Intravesical Therapies

• Heparin intravesical therapy can repair the damaged glycosaminoglycan layer and provide clinically significant symptom improvement 1, 2.
• Lidocaine intravesical therapy can provide rapid onset temporary relief of bladder pain 1, 2.

Third-Line: Cystoscopy with Hydrodistension

• Performing cystoscopy when second-line treatments fail can help determine anatomic bladder capacity and identify fibrosis-related capacity reduction 1, 4.
• Avoiding high-pressure and long-duration hydrodistension can minimize the risk of bladder rupture and sepsis 1.

Fourth-Line: Treatment of Hunner Lesions

• If Hunner lesions are identified on cystoscopy, fulguration and/or injection of triamcinolone can provide significant symptom relief 1, 2, 4.

Fifth-Line: Advanced Interventions for Refractory Cases

• Sacral neuromodulation may be considered if other treatments have not provided adequate symptom control 1, 2.
• Cyclosporine A may be administered orally for refractory cases 1, 2.
• Intradetrusor botulinum toxin A injections may be beneficial, but patients must accept the possibility of needing intermittent self-catheterization 1, 2.

Pain Management Throughout All Treatment Phases

• Initiating multimodal pain management approaches and maintaining them throughout treatment is recommended, with non-opioid alternatives strongly preferred due to the chronic nature of the condition 1, 2.
• Pain management alone does not constitute sufficient treatment, and underlying bladder symptoms must also be addressed 1, 2.

Critical Documentation and Patient Education

• Documenting baseline symptoms using validated tools such as the Interstitial Cystitis Symptom Index (ICSI) or Genitourinary Pain Index (GUPI) can help measure treatment effects 2.
• Educating patients that IC/BPS is a chronic condition with periods of flares and remissions requiring long-term management is essential 2.
• Setting realistic expectations, as treatment efficacy for any individual is unpredictable, and multiple therapeutic options may need to be tried before adequate symptom control is achieved 1, 2.

Hydroxyzine for Bladder Pain in Interstitial Cystitis/Bladder Pain Syndrome

Introduction to Hydroxyzine

• Hydroxyzine is an effective second-line oral medication option for treating bladder pain in adults with interstitial cystitis/bladder pain syndrome (IC/BPS) who have not responded adequately to first-line behavioral modifications and dietary changes 5, 6

Treatment Algorithm and Positioning

• The American Urological Association groups hydroxyzine together with amitriptyline, cimetidine, and pentosan polysulfate as second-line oral medications, with no hierarchy implied among them—meaning hydroxyzine is considered equally appropriate as any of these options 5, 6

Evidence Quality and Mechanism

• The body of evidence supporting hydroxyzine for IC/BPS is Grade B or Grade C, indicating moderate quality evidence 5
• The medication is associated with minor adverse events, making it a reasonable option before escalating to more invasive therapies 5

When to Use Hydroxyzine

• Hydroxyzine should be considered when the patient has not yet tried other second-line oral medications (amitriptyline, cimetidine, pentosan polysulfate) 5, 6

Multimodal Pain Management Context

• Hydroxyzine should not be used as monotherapy for pain management alone 5

Escalation Pathway if Hydroxyzine Fails

• If hydroxyzine proves ineffective after an adequate trial, consider alternative second-line oral medications (amitriptyline, cimetidine, pentosan polysulfate) 5, 6
• If hydroxyzine proves ineffective after an adequate trial, add or switch to second-line intravesical therapies (dimethyl sulfoxide, heparin, lidocaine) 5, 6